Hyperacute intra-arterial hcMSC delivery immediately after reperfusion promotes functional and electrophysiological recovery in an experimental reperfusion model, likely through early modulation of inflammatory and apoptotic responses in the peri-infarct tissue.
Key Findings
Results
Hyperacute intra-arterial transplantation of human cranial bone-derived mesenchymal stem cells (hcMSCs) immediately after reperfusion resulted in significantly faster neurological recovery compared with controls.
Transient middle cerebral artery occlusion (tMCAO) was induced in adult rats as the experimental model
hcMSCs or vehicle were administered intra-arterially immediately after reperfusion
Neurological recovery was assessed longitudinally using the modified neurological severity score (mNSS)
The hcMSC-treated group demonstrated significantly faster improvement in mNSS scores over the observation period compared to vehicle controls
Results
Intra-arterial hcMSC transplantation was associated with enhanced electrophysiological recovery of motor pathway function.
Motor pathway function was assessed using transcranial motor-evoked potentials (tcMEPs) longitudinally
The hcMSC-treated group showed enhanced electrophysiological recovery compared to controls
tcMEP assessment provided an objective, quantitative measure of corticospinal tract integrity distinct from behavioral scoring
This represents both functional and electrophysiological evidence of treatment benefit
Results
hcMSC treatment was associated with preservation of neuronal structural integrity in the peri-infarct cortex.
Histological analyses of peri-infarct tissue were performed during the acute phase
Neuronal structural integrity was preserved in hcMSC-treated animals compared to controls
Analyses focused on the peri-infarct cortex, the region at risk for secondary infarct expansion after recanalization
Preservation of neuronal structure correlated with functional improvements observed in behavioral and electrophysiological measures
Results
hcMSC transplantation attenuated inflammatory cytokines and apoptosis activity in peri-infarct tissue during the acute phase.
Molecular analyses of peri-infarct tissue were performed during the acute phase post-reperfusion
Inflammatory cytokine levels were reduced in the hcMSC-treated group compared to controls
Apoptosis activity was attenuated in peri-infarct tissue of hcMSC-treated animals
These findings suggest early modulation of inflammatory and apoptotic responses as a key mechanism of action
Results
hcMSC treatment was associated with upregulation of vascular endothelial growth factor (VEGF) in peri-infarct tissue.
VEGF upregulation was identified as part of the molecular response to hcMSC treatment in the acute phase
VEGF upregulation suggests a pro-angiogenic component to the therapeutic mechanism
This finding was identified through molecular analyses of peri-infarct tissue
VEGF upregulation supports neurovascular integrity restoration consistent with the study's framing around the 'no-reflow zone'
Results
Transcriptomic analysis revealed that hcMSCs are enriched in neurotrophic, angiogenic, and immunoregulatory factors compared to human bone marrow-derived mesenchymal stem cells (hbMSCs).
Transcriptomic profiles of hcMSCs were compared with those of human bone marrow-derived mesenchymal stem cells (hbMSCs)
hcMSCs showed enrichment in genes associated with neurotrophic factors, angiogenic factors, and immunoregulatory factors
This transcriptomic profile provides a biological basis for the observed therapeutic effects of hcMSCs
The comparison with hbMSCs suggests that cranial bone may be a preferentially suited MSC source for neurological applications
Background
The study investigated whether cranial bone-derived MSCs represent a biologically distinct cell source with particular relevance to post-stroke neurovascular protection.
Human cranial bone-derived MSCs (hcMSCs) were derived from cranial bone, a source anatomically proximate to the central nervous system
The study compared transcriptomic profiles of hcMSCs vs. hbMSCs to characterize source-dependent differences
The cranial bone source was hypothesized to confer a neurotrophic and neuroprotective secretome relevant to brain injury
The findings support hcMSC therapy as 'a biologically protective adjunctive strategy in the immediate post-recanalization setting'
What This Means
This research suggests that a specific type of stem cell derived from cranial (skull) bone can help the brain recover after a stroke, even when the blocked blood vessel has already been successfully reopened. Using a rat model of stroke, the researchers delivered these human cranial bone-derived mesenchymal stem cells (hcMSCs) directly into the artery immediately after restoring blood flow. Animals that received this cell treatment recovered neurological function faster and showed better recovery of the brain's motor pathways — the circuits that control movement — compared to animals that received no cells. The treatment appeared to work by reducing inflammation, limiting cell death, and promoting blood vessel repair in the vulnerable brain tissue surrounding the stroke injury.
A key aspect of this study is the comparison between cranial bone-derived stem cells and the more commonly studied bone marrow-derived stem cells. When the researchers analyzed the genetic activity of these two cell types, they found that cranial bone-derived cells naturally produce higher levels of factors that support nerve survival, blood vessel growth, and immune regulation. This suggests that where stem cells come from — in this case, bone near the brain — may influence how well they protect brain tissue after injury.
This research matters because successfully reopening a blocked artery (through clot-busting drugs or mechanical thrombectomy) does not always lead to good recovery for stroke patients — a phenomenon sometimes called the 'no-reflow' problem, where tissue continues to die even after blood flow is restored. This study suggests that delivering cranial bone-derived stem cells immediately after recanalization could serve as an add-on biological treatment to help protect the brain during this vulnerable window. While these findings are in animals and further research is needed before any clinical application, they support the idea of using cranial bone — which is routinely removed during neurosurgical procedures — as a convenient and biologically suitable source of protective stem cells.